



**KO_VI^-19 NA^ GAW~-AH^
NEH TA,_LE-AW~,NA^ HA,
MYA,-EU GA^ KAW^
DEU_.**

**1. KO_VI^-19 TCAW^
QHM~-EU JA^ GHA,
(ka_kaw-eh_se^)
-AH^ TA,_LE~-AW^
NA^HA,-EU DAW^ DEU_.**

Ko_vĩ-19 Na_gaw-ah ta le-aw na ha_eu ga kaw deu.

Ko_vĩ-19 Na_gaw-ah tcaw qhm hta_eu ja gha ga kaw-ah ta le-aw, na ha_eu ga kaw deu.

1. Ko_vĩ tcaw qhm hta_eu ja gha (ka_kaw-eh_se) tcaw ma leh ngeu na, ga kaw a_geu deu si_nya hta_eu lo hta.

Yaw ha-ah tcaw neh la_eu ja gha qhoe, a_geu je nga leh, ma tcaw mi na-eh ya si_nya hta meh. Mi tsa qhoe ta yu mui_jaw sa do-eu phaw haw-eu a_yui_deu (WHO) neh tsa tco hta_eu ka_kaw-eh_se deu teh-eh tcaw-eu tsa meh. Ja gha qhoe deu_a,

- (1) Byi^ten haw-eu In_dĩya mi qhah neh jah do-eu Covishield,
- (2) Byi^ten mi qhah neh jah do hta_eu, AstraZeneca,
- (3) A_me li^ka mi qhah neh jah-eu, Pfizer, Moderna, Janssen,
- (4) La_bui mi qhah neh jah-eu, Sinopharm (Beijing Institute of Biological

Products co- Ltd), CoronaVac (Sinovac) heu deu meh.

Sinopharm (BIBP) haw-eu, Sinovac ja gha heu deu hteh tsa, (a_ye paw) ngeh zm nya meh leh, 2021 qo me_ba la haw-eu ju_ba la ah mi tsa qhoe ta yu mui_jaw sa do-eu phaw haw-eu a_yui_deu neh na ga kha hta_eu meh. **La_bui mi qhah neh jah do-eu, Sinopharm (Wuhan Institute of Biological Products Co-Ltd) haw-eu, In_dĩya mi qhah neh jah do-eu, Covaxin leh khu-eu ka_kaw-eh_se heu deu-ah mi tsa qhoe ta yu mui_jaw sa do-eu phaw haw-eu a_yui_deu pyeh tse lu-aw, tsa ma tco neh-a si.**

Qhoe u ta, ja gha qhoe, gha byah, ma byah, a yam bu-i, ma bu-i-eu haw-eu, ja gha tcaw neh-eu tsaw ha deu noe htm choe-eu tsaw ha nga lo leh ja gha ma tcaw mi na-eh pyeh tse-eu lo meh.

2. Ko_vĩ-19, Ka_kaw-eh_se tcaw gha na a_geu ti-ah keu ni ka kaw-eh nya hta.

Mi tsa qhoe ta yu mui_jaw sa do-eu phaw haw-eu a_yui_deu (WHO) neh tsa tco gha hta_eu ka_kaw-eh_se deu-ah pyeh tse du hta_eu_a.

| | Ko_vi^ ka_kaw-eh_se^ deu_ | Ko_vi^ na_gaw^ ya kham_-eu deu_-ah^ lo_qhm_nya-eu a^ti^ | Ko_vi^ na_gaw^ yaw qa^/ yaw heh^-ah^ lo_qhm_nya-eu a^ ti^ |
|----|--|---|---|
| 1. | Pfizer by BioNtech Comirnaty | 91.3% | 95.3% |
| 2. | AstrZeneca-University of Oxford by SK Bio | 76% | 85% |
| 3. | Covishield by SII | 66.7% | 92% |
| 4. | Janssen by Johnson & Johnson | 72% | 86% |
| 5. | Moderna | >90% | >95% |
| 6. | Sinopharm by Beijing Biolnstitute of Biological products Co. Ltd., | 79% | Pyeh^ tse^ du_ hta_-eu_ ma_ ja^ si_ |
| 7. | Coronavac (Sinovac) by Sinovac Biotech Ltd | 51% | 100% |

* Ka_kaw-eh_se^ heu deu_-a_, zaw^qa^-eu ko_vi^-19 na_gaw^-ah^, a^ti^ hti_ ti^-ah^ keu^ ni ka_kaw-eh_nya-eu qaw_, ko_vi^ ma_ bi nyaw_la^ ni-a_, ma_ lo_qhm_nya-eu mi^neh, (mask), meh_ tsah_ tsah_-eu, sa^ bya_ neh 20 seh^ kan^ a_la_ dzui_-eu haw^-eu, tsaw^ha_u_i_ gha ga^ma_i^ni yah^-eu, ga^khah^ heu deu_-ah^ yaw mui_-eh^ ya chaw hteh meh.

3. Ko_vi^ tcaw^qhm_-eu ja^ gha_ (ka_kaw-eh_se^) heu, a_ jo^-eh^ gheh-eu tsaw^ha_ deu_ tcaw^-eu tsa_ hta.

A^qo_ (18) qo_-ah^ neh la_ta^ yaw_gha_ na lu_ ko_vi^ ka_kaw-eh_se^ tcaw^ nya-eu qaw_,

- Na_gaw^nyaw_ le^ nya-eu yaw khaw^, yu_mui_ jaw^sa^ do^-eu phaw haw-eu ga^ m^za_(sa_la_ghon_/ ma) deu_ haw^-eu,
- Ko_vi^ nyaw_ le^ na^, na_gaw^ dm_-eu (na_gaw^yaw qa^) tsaw^ ha_ deu_ (a^qo_ qaw^la^-eu tsaw^ha_, maw^ do la_ qhoe^ na^ gaw^ nui je_ ah^-eu deu_)` heu lo_-eh^ gheh-eu tsaw^ ha_ deu_-ah^ je_hu_ tcaw^ neh_-eu tsa_ meh “ leh^tsaw^gah^ ah^-eu tsaw^ ha_ deu_ eh^-eu meh.
- Shi_da^-eu, oi^soi yaw choe^ah^-eu, mi^du_su_-eu, sha_tsah_sha_ paw_na^-eu, beh^si_ na^-eu haw^-eu, a^yam_ ghaw_ myah^ ni na^-eu na^ gaw^(HIV) lo^e_ a^ maw^ u^-aw^, E_A_Ti_ (ART) ja^gha_ htu daw^ lu_-eu tsaw^ ha_ deu_,ka_kaw-eh_se^ tcaw^-eu tsa_ meh.

4. Tsaw^hha_u a_u geu_u deu_u ko_uvi^h ka_ukaw-eh_u se^h tcaw^h-eu ma_u tsa_u hta.

- Ko_uvi^h na^hlu_u-eu tsaw^hha_udeu_u, ko_uvi^h na^hgaw^h a^hgheh^h bya_ula^h hta_u-aw^h nui noe_u dze^h pha_u-eh^h gheh-eu tsaw^hha_u deu_u.
- A^hqo_u(12) –ah^h neh la_u o^h phaw-eu_u za_u deu_u(Pfizer) leh^h khu^h-eu ko_uvi^h ka_ukaw-eh_use^h ma_u ngeu^h na^h nui je_u ka_ukaw-eh_use^hdeu_u-a_u, (18) qo_u la_u o^h deu_u ma_u tcaw^h nya-a.
- Ka_ukaw-eh_use^h neh_u-eh^h ma_u tsa_u le^h-eu tsaw^h ha_u deu_u tcaw^h-eu ma_u tsa_u-a.
- Dzeu^h la^h ngeh nui je_u ka_ukaw-eh_use^h tcaw^h ngeh ma_u tsa_u le^h-eu baw-eu deu ma_u ya tcaw^h-a.
- Za_u phi lu_u-eu deu_u,(nui je_u ka_u kaw-eh_use^htcaw^hlu_u-eu) tcaw^h-eu ma_u tsa_u-a.

Ja^hgha_u-ah^h ma_u tsa_u le^h-eu baw-eu tsaw^h ha_u deu_u, ka_ukaw-eh_u se^h ma_u tcaw^h mi na^h-eh^h na_u ngeh neh sa_ula_u ghon_u deu_u-ah^h ya bi si_u hta_u meh.

Za_u phi lu_u-eu a_u ma deu_u, ko_uvi^h nyaw_u le^hna^h, na^h gaw^h dm_u-aw^h,(na^h gaw^h yaw choe_u) u_uma^h la_uqhoe^h phi lu_u-eu, za_u-ah^h keu^hni, deu_u le^h nya-eu mi^h neh, ko_uvi^h ka_ukaw-eh_use^h tcaw^h hta_u pha_u-eh^h gheh-eu qaw_u, ka_ukaw-eh_use^h deu_u la_uqhoe^h, za_u phi lu_u-eu a_u ma deu_u gha^h du_u, yaw mui_u je_u haw^h-eu, yaw doe^h je_u po^h du_u po^h maw^h hta_u-eu ma_u ja^h-eu mi^hneh, si_udu_u maw^h du_u nya-eu sa_ula_u ghon_u/ma_u deu_uneh_u-eh^h baw_u dza_u-aw^h, ya tcaw^hmeh.

5. Ko_uvi^h ka_ukaw-eh_use^h tcaw^h na^h a_u je_u-eu gha^h du_u gui_ulah_u baw-aw^h, a_u je_u-eu gha^h du_u gui_u lah_u ma_u pyeu_u hta.

Ko_uvi^h ka_ukaw-eh_use^h heu, eh^h hta_u-eu a^hpo^h tcaw^h byah na^h la_u o^h phaw eh^h hta_u-eu lo_u-eh^h gui_u lah_u baw meh.

- ✓ Ko_uvi^h-19 na^h gaw^h nyaw_u la^h qaw_u ma_u ya na^h choe_u-eu u_u ta_u, shi^h-eu tsaw^h ha_u yaw cui^h meh.
- ✓ Ko_uvi^h-19 na^h gaw^h nyaw_u la^h-eu haw^h-eu, a_u chaw_u-ah^h nyaw-i^h-eu yaw cui^h meh.
- ✓ Ko_uvi^h-19 a^hboe_ua^hmaw^h a^hjeu_u pha^h la^h ga^h lo_u qhm_u nya meh.

Ka_ukaw-eh_use^h a_ugeu je_u ma_u kha_u na^h gaw^h ma_u bi nyaw_u la^h ni 100% ma_u lo_u qhm_u nya-eu mi^h neh, na^h gaw^h nyaw_u le^h-eu heu-a_u, a^hqo_u, boe_u mui_u ma_u mui_u-eu haw^h-eu, gha_u byah, ma_u byah-eu ga^h neh qaw_uta_u-aw^h, na^h gaw^h lo_u qhm_u nya-eu ga^h qhah dzeu^h-aw^h nyaw_u la^h-eu(breakthrough infection) meh. Ka_u kaw-eh_use^h a^h po^h tcaw^h byah hta_u-eu qaw_u na^h gaw^h nyaw_u la^h nya-eu ga^h ka_ukaw-eh_use^h qhah dzeu^h-aw^h na^h gaw^h a^h maw^h nyaw_ula^h-eu (Vaccine breakthrough cases) leh^h khu^h-eu meh.

Qhoe mĩ neh, ka₁kaw-eh₂sẽ ãpõ tcaw̃ byah hta₁-eu₂ qaw₁, nã gaw̃ lo₁ qhm₁ nya-eu gã khah̃ pyeu₁-eu, meh₁ tsah₁ tsah₁-eu, a₁la₁ hti₁ qheh₁ ma₁ hta₁ ni dzui₁-eu, ãkha₁ 6 pe₁ khã ni jaw̃-eu, tsaw̃ ha₁ bym̃ gha gã ma₁ ĩ ni jaw̃-eu, heu deu₁ lo₁ meh.

Ka₁kaw-eh₂sẽ tcaw̃-eu ba₁ da neh gui₁ lah₁ ma₁ pyeu₁-eu je₁-a₁, jãgha₁ tcaw̃ gha₁ nã phya₁ lã-eu, khuĩ gu₁ la₁ gu₁ ghah-eu, jũleh̃ ni gheh-eu, jã gha₁ tcaw̃-eu gã nẽ lã-aw̃ nã-eu, heu deu₁ pyeu₁ nya-eu meh. Eh̃ qaw₁ hti₁ pãna deu₁ nyi₁ nah byah lã nã hta₁ lẽ gã ya maw̃-eu meh.

6. Ko₁vĩ ka₁kaw-eh₂sẽ tcaw̃-eu ghã du₁ a₁ jõ-eh̃ ya leh₁ hm₁ hta₁ hta.

Ka₁kaw-eh₂sẽ ma₁ tcaw̃mi nã-eh̃

- Gha₁na₁ yaw mui₁-eh̃na₁-aw̃ jaw̃ sã dõ-eu lo₁ meh. (jaw̃sã ma₁ dõnã, ka₁kaw-eh̃sẽ tcaw̃-eu ma₁ tsa₁-a.
- Nãgaw̃ hti₁ je₁ je₁ ba₁ da neh ma₁ tceh̃ lẽ ni ya daw̃ lu₁-eu jã gha₁ deu₁, ka₁kaw-eh₂sẽ ma₁ tcaw̃ mi nã-eh̃ ma₁ daw̃ ni na₁-eu ma₁ lo₁-a.
- Maw̃do gha₁ bi ba₁-ĩnya-eu “sa₁tĩyaw-ẽ” leh̃ khũ-eu jãgha₁ haw̃-eu mãdeh₁ (ken₁sa₁) jã gha₁ daw̃ lu₁ nã, nã gaw̃ lã sã lu₁-eu sa₁ la₁ ghon₁ deu₁ neh₁-eh̃ na₁ ngeh neh ya baw₁ dza₁ hta₁ meh.
- Boe₁baw-eu (nãgaw̃ hti₁ je₁ pha₁ah̃-eu) ma₁eh̃, Jãgha₁ hti₁ je₁na ma₁ tceh̃ lẽ ni ya daw̃ lu₁-eu ma₁ eh̃, ka₁kaw-eh₂sẽ tcaw̃ neh₁-eu sa₁la₁ ghon₁ deu₁-ah̃nã ngeh neh ya bi si₁ meh.

Ka₁kaw-eh₂sẽ ma₁ tcaw̃mi nã-eh̃ haw̃-eu, tcaw̃gha₁-aw̃,

- Gha₁ pyeu₁-eu dzã, ghaw₁nyoẽ dzã nyoẽhaw̃-eu ã si₁ ãlu deu₁ ya dza₁ meh.
- Jĩba₁ma₁ ya daw̃-a. (ghaw̃maw̃ gui-aw̃ u₁ peh₁peh₁-eu mĩ neh meh.
- Hti₁ jaw̃-i₁ma₁dza₁haw-eu₂dzã dza₁haw-eu, ma₁zm₁haw, ma₁ leh₁ haw-eu ã gheh̃ leh₁mui₁leh₁ jũ-eu myaw₁, kheu kha deu₁, ma₁ya zeũ zm₁-a. (Hti₁ je₁ pha₁ pyeu₁ lã nã, qhoẽ dza₁-eu₂, zm₁-eu₂ ba₁ da₁ neh pyeu-eu haw̃-eu, jã gha₁ba₁da₁neh pyeu₁-eu leh̃ma₁tsẽpã nya-eu mĩneh meh.)

Ka₁kaw-eh₂sẽ tcaw̃gha nã

- • Jã gha₁ tcaw̃ neh₁ la₁-eu₂ jaw̃ du₁-ah̃, na₁li₁ 30 mĩnĩ byah ni ya lo₁ haw meh. (Jãgha₁ ma₁tsa₁ lẽ ni pyeu₁ lãnya-eu, shi₁ga₁-ĩ-eu, nui ma cheh̃ htah₁dui₁ni pyeu₁lã-eu, sa₁ ghaw̃ qhah₁ su₁lã-eu, hti₁ htaw na doe ni, mã toẽ toẽ nẽ dõ lã-eu, myãqhah₁ nẽlã, phu₁lã-eu heu deu₁ pyeu₁ lã nã, jã gha₁yaw khaw̃-eh̃ya lã sã-eu mĩ neh meh.)
- Jã gha₁ tcaw̃-eu mã qheh₁ ma₁ bi phu₁ lã-eu ghã du₁ haw̃-eu, ma₁ bi gaw̃-eu ghã du₁ ngeh̃khm (ye₁kheh̃) neh deh₁ da₁ nya meh.

- Gheh nya na³ nyi² nah byah ni gha² na² yaw mui²-ah³ na²-aw³, u²ci² yaw mui² -eh³ yu² deh³ yaw². Gha²qa³si²-aw³ ni³gha²-eu, m³ myaw² m³-eu heu deu² ka² kaw-eh² se³ tcaw³-eu² (7) nah la² qhoe³ ma² ya m³-a. (l³cu² i³ di² di²-eu, seh³ be³ dzi²-eu, ceh³-eu, yaw khah ba²-eu, baw dui³ beh³/ teh³-eu,)

7. Ko²vi³ ka² kaw-eh² se³ a² ga³ tcaw³-i³ na³ mui² dzeh² hta.

Ja³gha² byaw²-i³-eu², gha² hte²-i³-eu² ga³ ma² ya qhah² lah³ pha²-eh³,

- Ma³ ma³ ni gheh²-eu ko²vi³ka² kaw-eh² se³ sha ah³ la²-eu² yaw du² baw²-eu,(a²ma² khan²) a³ma² a³mu³, ko²ma²ni².
- Ka² kaw-eh² se³ hta²-eu a³hta² a³ti³ti³ hta²-eu² yaw tceh² yaw lah³ tsa² ni je² hm² hta²-eu²,
- Yaw mui²-eh³ ha³ lah³ je² hm²-aw³ yu³ la²-eu²,
- Ja³gha² tcaw³ ngeh, ja³ gha² hta²-eu, zm²-eu zah³ sah³ qo²-ah³ yaw mui²-eh³ chaw hteh²-eu.,
- Ka² kaw-eh² se³ zm²-eu ga³ kaw³-ah³ ta² le³-aw³, ga³ kaw³(then² dan³) yaw mui²-eh³ dzaw gha² hta²-eu² bym²-eu, byeh³-eu tsaw³ ha² jaw³-eu ga³.,
- Jah choe³, noe² htm² choe³-eu sa² la² ghon/ma deu² jaw³ ga³ teh²-eh³ ka² kaw-eh² se³ tcaw³-eu tsa² meh. Byaw²-i³, hte²-i³-eu² ka² kaw-eh² se³ deu² za² la³ ga³ ya yah³ meh.

8. Ko²vi³ ka² kaw-eh² se³ ma² byaw²-i³ ni, a³ yam² a³ myah keu³ ni gm² hta.

Ko²vi³ ka² kaw-eh² se³-a², po³ tse³ po³ do³-aw³ yaw shui² jah³ do³-eu² mi³ neh, ma² byaw²-i³ ni a³ yam² a³ myah ni gm²-eu leh³ ma² pyeh³ tse³ du² dah²-eu² si² mi³ neh, ma² eh³ du² nya-a si².

9. La² bui² mi³ qhah² neh jah³ do³-eu² Sinopharm CoronaVac (Sinovac) haw³-eu, In² di³ ya³ mi³ qhah² neh jah³ do³-eu² Covishield ko²vi³ ka² kaw-eh² se³-eu² ga³ kaw³ si nya maw² mi³-a.

| | Sinopharm (BBIBP-CorV) | CoronaVac (Sinovac) | Covishield |
|--|--|----------------------------------|--|
| Jah ³ do ³ -eu ² ko ² ma ² ni ² | Beijing Institute of Biological Products Co. Ltd | Sinovac life Sciences Co, Ltd | Serum Institute of India Pvt. Ltd (AstraZeneca Ko ² ma ² ni ² haw ³ -eu, Oxford teh ³ ka ² tho ² gm le ³ -aw ³ jah ³ do ³ -eu ² |

| | Sinopharm (BBIBP-CorV) | CoronaVac (Sinovac) | Covishield |
|---|---|--|---|
| Ja ^h gha _u yaw _u je _u yaw _u tsa | Vai ^h ra ^h a ^h maw ^h gha _u hte _u -i ^h ni, (Inactivated virus) la ^h pyeu _u -aw ^h jah ^h -eu _u | Vai ^h ra ^h a ^h maw ^h gha _u hte _u -i ^h ni, (Inactivated virus) la ^h pyeu _u -aw ^h jah ^h -eu _u | Vai ^h ra ^h a ^h maw ^h phi ah ^h la _u -eu a ^h maw ^h (viralvector) –ah ^h neh hti _u ti ^h jah ^h do ^h -eu _u . |
| Ja ^h gha _u ya je _u hm _u hta _u -eu yaw lah ^h a ^h ti ^h | 2 ah ^h neh 8 Di _u gi _u li _u seh ^h si ^h ya ^h la _u qhoe ^h (Ma ^h tca _u la _u qhoe ^h yaw lah ^h haw nya-eu je _u ah ^h) | 2 ah ^h neh 8 Di _u gi _u li _u seh ^h si ^h ya ^h la _u qhoe ^h | 2 ah ^h neh 8 Di _u gi _u li _u seh ^h si ^h ya ^h la _u qhoe ^h |
| ya tcaw ^h byah- eu a ^h po ^h | 2 po ^h , (yaw beh po ^h tcaw ^h gha _u -aw ^h 3 jaw , 4 jaw kha-i ^h -aw ^h , 2 po ^h hti _u po ^h pha ^h ya tcaw ^h meh.) | 2 po ^h , (yaw beh po ^h tcaw ^h gha _u -aw ^h 2 jaw , 4 jaw kha-i ^h -aw ^h , 2 po ^h hti _u po ^h pha ^h ya tcaw ^h meh.) | 2 po ^h , (yaw beh po ^h tcaw ^h gha _u -aw ^h 4 jaw ,6 jaw kha-i ^h -aw ^h (ma) 8 jaw, 12 jaw-ah ^h 2 po ^h yaw _u po ^h tcaw ^h yaw _u . |
| Na ^h gaw ^h ba _u da neh pyeu _u la ^h -eu je _u -ah ^h lo _u qhm _u nya –eu gha _u | 79% (2 po ^h tcaw ^h gha _u mi ^h tsa 14 nah-ah ^h neh dah _u beh-aw ^h) | 51% (2 po ^h tcaw ^h gha _u mi ^h tsa 14 nah-ah ^h neh dah _u beh-aw ^h) | 66.7% |
| Ko _u vi ^h na ^h gaw ^h yaw dm _u (yaw qa ^h) ah ^h lo _u qhm _u nya-eu gha _u | Po ^h du _u hta _u -eu _u ma _u ja ^h si _u | 100% | 92% |
| Zm _u -eu a khaw- a _u za , ma za | A khaw-a _u bi _u gha _u (7 me _u ba la 2021) | A khaw-a _u bi _u gha _u (1 ju _u ba la 2021) | A khaw-a _u bi _u gha _u (16 fe _u phaw _u ba _u li _u 2021) |
| Si _u nya hta _u pha _u -eh ^h gheh- eu nui je _u ga ^h kaw ^h | <ul style="list-style-type: none"> A^hqo_u 18 qo_u la_u ta^h deu_u teh_u-eh^h ya tcaw^h meh. A_uchoe^h daw^h za_u a_uma deu_u qaw_u tcaw^h nya meh. Za_uphi lu_u-eu a_u ma deu_u-ah^h tcaw^h nya, ma_u tcaw^h nya-eu ma_u po^h du_u hta_u-eu_u mi^hneh, za_uphi lu_u-eu deu_u-ah^h tcaw^h na^h mui_u-eu, ma_u mui_u-eu, sha^hnoe_u-aw^h ya tcaw^h meh. | | |

Sinopharm ka_ukaw-eh_use^h-a_u, yaw beh po^h tcaw^h gha_u-aw^h, (3) jaw ma_u byah la^h mi
na^h-eh^h, nyi_u po^h hti_u po^h pha^h ya tcaw^h na^h, pha^h tcaw^h hteh_u-eu ma_ulo_u-a. Yaw beh po^h tcaw^h
gha_u-eu (4) jaw dzeh_u-i^h-eu qaw_u, nyi_u po^h hti_u po^h ma_u ya tcaw^h-eu si_u na^h, a_u geu ga^h tcaw^h

nya-eu nga leh, yaw khaw-eh ya tcaw^meh. Ka kaw-eh-se heu je-a, nyi-po^_{eu} yaw kha a yam a myah ni bi kha na mui dzeh-eu ga kaw, nym keu ni ma po du dah-a si.

* Covishield ka kaw-eh-se heu je-a, yaw beh po^ tcaw^ gha na, 8 jaw-ah neh 12 jaw kha-i-aw nyi po^ hti po^ tcaw^ nya meh leh eh hta-eu meh. Eh hta-eu lo-eh ma ya tcaw^_{eh}, 12 jaw dzeh ni pha kha-i-eu qaw, a dah beh ga neh tcaw^_{eu} ma lo ni, nyi po^ hti po^ tcaw^ nya meh leh eh hta-eu meh. I'taw la taw-eu sha-eu mi neh, a kha kha-i-eu qaw jaw sa do^_{eu} phaw haw-eu a yui deu ga kaw kaw neh la-eu lo-eh tcaw^ nya meh.

10. Ko_{vi}^⁻¹⁹ na gaw na gha na ka kaw-eh-se ma tcaw^ qaw geu nya meh lo.

Ko_{vi}^⁻¹⁹ na gaw na gha-eu qaw ka kaw-eh-se ya tcaw^ meh. A je mi neh eh na, ko_{vi}^ na-aw hta le gha-eu qaw, na gaw ma pyeu la ni, a myah ni gm-eu ma si tceh nya-a. leh tsaw gah ah-eu deu eh-eu meh. Ko_{vi}^ na gha-eu tsaw ha deu na gaw ma pha pyeu po^ la meh leh noe-eu qaw, pyeu po^ la nya-eu phaw mya dzeh meh. Ko_{vi}^ na gha-eu tsaw ha deu ka kaw-eh-se tcaw^ na, gha (ko_{khan}a) byah dzeh meh leh tsaw gah ah-eu tsaw ha deu po^ du hta-eu meh.

11. Ko_{vi}^⁻¹⁹ na gha-eu tsaw ha deu na gaw hta le gha na a yam a myah ni kha-i-aw, ka kaw-eh-se ya tcaw^ hta.

Ko_{vi}^⁻¹⁹ na-eu tsaw ha deu na gaw-eu a gheh byo ji-aw, yaw ha la qhoe-eu ko_{vi}^ a maw a chaw-ah ma pha nyaw-i nya ngeh a yam,

- Ko_{vi}^ na gaw pyeu nga leh ya si ngeh nah neh dah beh-aw, (a dzeh ma dzeu-eu deu) 10 nah byah la-aw, za nah, ma phya ni pyeu-i na,
- Na gaw yaw dm,(yaw qa) na-eu deu na gaw nyaw le-aw (20) nah dzeh ji na, ka kaw-eh-se tcaw^ nya meh.
- Na gaw nyaw le-aw, (na gaw a dzeh qa-eu deu) shi yaw ba (thoe ye ci) neh ya la sa-eu tsaw ha deu-a, na gaw na-eu (90) nah byah la-aw neh ka kaw-eh-se ya tcaw^ meh.

12. Ko_{vi}^⁻¹⁹, ka kaw-eh-se a po^ tcaw^ byah gha ji na, na gaw-ah lo qhm nya-eu gha do^ la-eu, ma do^ la-eu ya si ni, (Antibody test kit) kheu kha neh dza haw nya meh lo.

Ma dza haw nya-a. A je mi neh eh na, ko_{vi}^ ka kaw-eh-se tcaw^ gha na, na gaw-ah lo qhm-eu gha, ah, ma ah-eu ya si ni, kheu kha heu neh dza haw-eu gha du tsaw gah ah-eu tsaw ha deu ma meh neh hta-a. Kheu kha heu-a, dzeu la ngeh ko_{vi}^⁻¹⁹ na gaw na haw ya, ma na haw ya-eu ya si ni dza haw-eu gha du zm-eu teh meh.

13. Ko_{vi}ˆ-19, Ka_{kaw}-eh_{se}ˆ yaw beh poˆ tcawˆ gha-awˆ, nyi_{po}ˆ hti_{po}ˆ tcawˆyam_{tsa} laˆ ngeh, ko_{vi}ˆ-19, naˆgawˆ aˆ ghehˆ bya_{la}ˆ naˆ,(phya_{eu}, u_{tsoe}_{tsoe}-eu, tceh_{htah} nyaw_{eu}) ka_{kaw}-eh_{se}ˆ tcawˆnya meh loˆ.

Naˆ gawˆ aˆ ghehˆ deu_{do}ˆ lu_{ng}eh, ka_{kaw}-eh_{se}ˆ tcawˆ-eu ma_{tsa}-a. Naˆgawˆ aˆ ghehˆ deu_{byo}ˆ jiˆgha_{eu} miˆtsa ka_{kaw}-eh_{se}ˆ ya tcawˆ meh. Ko_{vi}ˆnaˆ gawˆ naˆ lu_{eu} tsawˆha_{deu} ka_{kaw}-eh_{se}ˆ tcawˆ-eu ghaˆ du_aˆ yam_aˆ myah ni ya bi khaˆ-eu gaˆ kawˆ, la_{ta}ˆ phaw ehˆ meh_{dzeu}ˆ hta_{eu}ˆ na_{ba} (11)- ahˆ haw yaw_{eu}.

14. Ko_{vi}ˆ-19, ka_{kaw}-eh_{se}ˆ yaw beh poˆ tcawˆ gha_{eu}ˆ gaˆ ko_{vi}ˆ naˆ gawˆ naˆ laˆ-awˆ hta_{le}ˆ gha_{na}ˆ, ko_{vi}ˆ ka_{kaw}-eh_{se}ˆ nyi_{po}ˆ hti_{po}ˆ tcawˆ nya meh loˆ.

Ka_{kaw}-eh_{se}ˆ nyi_{po}ˆ hti_{po}ˆ tcawˆ nya meh. Ehˆqaw_{na}ˆ gawˆ ma_{hta}ˆ tcehˆ leˆ-eu_{ngeu}ˆ naˆ, na_{ba} (11) -ahˆ ehˆ dzeuˆ ya_{eu}ˆ lo_{eh}ˆ ya chaw hteh meh.

15. Aˆqo₆₀ (60) neh la_{ta}ˆ phaw_{eu}ˆ, sha_{tsah}_{na}ˆ-_{eu}, nui ma naˆ gawˆ, shi_{da}ˆ, oiˆshoi choeˆ, haw_{eu}ˆ naˆ gawˆ nui je_{ah}ˆ-_{eu} tsawˆ ha_{deu}ˆ ka_{kaw}-eh_{se}ˆ tcawˆ naˆ, a_{jo}ˆ-ehˆ, (side effect) tsa-iˆ nya eu la. Ka_{kaw}-eh_{se}ˆ tcawˆ-eu tsa_{eu}ˆ, ma_{tsa}-_{eu} si nya maw_{mi}-a.

Sha_{tsah}ˆ naˆ-_{eu}, nui ma naˆ gawˆahˆ-_{eu}, shi_{da}ˆ-_{eu}, oiˆshoi choeˆ-_{eu}, behˆsi_{na}ˆ-_{eu}, tsawˆ ha_{deu}ˆ teh_{ma}ˆ ngeuˆni, aˆqo₆₅ la_{ta}ˆ deu_{ko}ˆvi₁₉ nyaw_{le}ˆnaˆ, a_{chaw}ˆ naˆ ma_{tse}ˆ, naˆ gawˆ choeˆ dzeh_{aw}ˆ, qhah_{ya}ˆ lahˆ-_{eu} miˆneh, a_{chaw}-_{eu} je_{hu}ˆ neh ko_{vi}ˆ ka_{kaw}-eh_{se}ˆ ya tcawˆneh_{meh} lehˆ, tsawˆ gahˆahˆ-_{eu} tsawˆha_{deu}ˆ ehˆ hta_{eu}ˆ meh.

Qhoeˆmiˆneh ka_{kaw}-eh_{se}ˆ ma_{tcaw}ˆ-ehˆ ma_{byeh}ˆni ya tcawˆ meh. Ka_{kaw}-eh_{se}ˆ ma_{tcaw}ˆmi naˆ-ehˆ yaw_{ha}-_{eu} mawˆ doˆ la_{qhoe}ˆ naˆ gawˆ a_{geu}ˆ je_{ah}ˆ-_{eu} gaˆ kawˆ jaˆ gha_{tcaw}ˆ neh_{eu} sa_{la}ˆ ghon_{ah}ˆ na_{ng}eh neh bi si_{hta}ˆ yaw_{eu}. Mawˆdo la_{qhoe}ˆ naˆ lu_{eu}ˆ naˆ gawˆ deu_{qaw}ˆ jaˆ gha_{la}ˆsaˆ-_{eu} lo_{meh}.

16. Loˆe_{HIV} aˆmawˆ uˆ-_{eu} miˆ neh E_AT_I (ART) jaˆ gha_{htu}ˆ dawˆ lu_{eu}ˆ tsawˆ ha_{deu}ˆ ko_{vi}ˆ-19, ka_{kaw}-eh_{se}ˆ tcawˆ nya, ma_{tcaw}ˆnya-_{eu} si_{nya} maw_{nya}.

Ko_{vi}ˆ-19, ka_{kaw}-eh_{se}ˆ deu_{mya}ˆ ni hti_{pa}ˆ, Loˆe_{HIV} nyaw_{le}ˆ hta_{eu}ˆ tsawˆ ha_{hti}ˆ paˆ na deu_{ah}ˆ dza haw hta_{eu}ˆ jaˆ gha_{meh}. Qhoeˆ lo_{eh}ˆ pyehˆ tseˆ du_{hta}-_{eu} ma_{byah}ˆ leˆ dah_{eu}ˆ qaw_{yu}ˆ mui_{jaw}ˆ saˆ doˆ-_{eu} phaw neh tsa_{tco}ˆ gha_{hta}-_{eu} ka_{kaw}-eh_{se}ˆ deu_aˆ, (HIV) loˆe_{na}ˆ-_{eu} tsawˆ ha_{deu}ˆ ghaˆ du_{tsa}ˆ-iˆ-_{eu} je_{ma}ˆ jaˆ lehˆ ehˆ hta_{eu}ˆ meh. Qhoeˆ u_{ta}ˆ, ka_{kaw}-eh_{se}ˆ heu jahˆ doˆ ngeh vaiˆraˆ aˆmawˆ yaw deh_{neh} jahˆ-_{eu} ma_{ngeu}-_{eu} miˆ neh, loˆe_{na}ˆ-_{eu} deu_{gha}ˆdu_{na}ˆ gawˆ nui je_{nyaw}ˆlaˆ gaˆ ma_{ya} guˆ-a. Lehˆ ehˆ hta_{eu}ˆ meh.

Ko_{vi} ka_{kaw-eh}se_h haw_{-eu}, E_ATi_u (ART) ja^hgha_u yaw kha_u bah_{-i}-eu je_u ma_u ja^h-eu mi^h neh, ka_{kaw-eh}se_h tcaw^h gha_u na^h (ART) ja^h gha_u pha^h daw^{tca} nya meh. Eh^h maw_{-eu} je_{-a}, si_u di_u 4 (CD4 count) yaw cui^h tsaw^h ha_u deu_u ko_{vi} ka_{kaw-eh}se_h tcaw^h ngeh na^h gaw^h-ah^h lo_u qhm_u nya-eu gha_u bya la^h-eu yaw cui^h qaw_u, Yaw_u je_u yaw_u tsa^h-i^h nya-eu ga^h kaw^h ma_u po^h maw^{hta}-a_u si_u. Mi^h qhah_u hti_u pa^h na deu_u (CD4 count) 200/ ku^h ba^h mi_u li_u mi_u ta_u la_o ja^h lu_{-eu} tsaw^h ha_u deu_{-ah} ka_{kaw-eh}se_h meh hu hu sa_u tcaw^h neh_{-eu} ja^h la^h la_u qhoe^h daw^{ah} hta_{-eu} meh. Gha_u ma_u byah-eu tsaw^h ha_u deu_u haw_{-eu}, na^h gaw^h nui je_u (boe_{baw}-eu) ah^h-eu tsaw^h ha_u deu_u ko_{vi} nyaw_u le^h na^h qhah_u ya lah^h-eu mi^h neh, ka_{kaw-eh}se_h je_u hu ya tcaw^h-eu meh leh^h eh^h hta_{-eu} meh.

17. Ma_{baw} a_{ma} (za_{ma} phi le^h nya-eu) ja^h gha_u (ko_{ghon} ta^h se^h) daw^h lu_{-eu} deu_u ko_{vi} ka_{kaw-eh}se_h tcaw^h nya meh lo^h. Ka_{kaw-eh}se_h tcaw^h gha_u mi^h tsa_u, a^h yam_u a^h myah ni kha^h-i^h-aw^h, ma_{baw} a_{ma} ja^h gha_u pha^h daw^h tca_u nya hta.

Yaw nym^h nym^h leh^h ya eh^h na^h, ma_{baw} a_{ma} ja^h gha_u daw^h lu_{-eu} a_u ma deu_u qaw_u ko_{vi} ka_{kaw-eh}se_h tcaw^h nya meh. Leh^h tsaw^h gah^h ah^h-eu deu_u eh^h hta_{-eu} meh. Eh^h qaw_u, ma_{baw} a_{ma} ja^h gha_u daw^h lu_{-eu} a_u ma deu_u ka_{kaw-eh}se_h tcaw^h ma leh^h ngeu^h na^h, ja^h gha_u tcaw^h neh_{-eu} sa_u la_u ghon_u deu_u neh_{-eu} eh^h je_u hu_u baw_u dza_{-aw} tcaw^h na^h mui_u dzeh_u meh.

Ko_{vi} ka_{kaw-eh}se_h hti_u pa^h na deu_u la_u qhoe^h, shi_u ym^h le_u nya-eu hti_u je_u ah^h ga^h po^h maw^h du_u hta_{-eu} meh. E_u ga_u lan_u (UK) mi^h qhah_{-ah} po^h tse^h maw^h hta_{-eu}, (Thu^h te_u tha_u na^h) la_u qhoe^h, (20) jui^h gha_u (20 lam) tcaw^h-eu ga^h, (79) gha_u shi_u ym^h le^h-aw^h, qhoe^h-eu la_u qhoe^h (19) gha_u shi^h-eu ga^h ya maw^h-eu meh.

Ma_{baw} a_{ma} ja^h gha_u daw^h lu_{-eu} a_u ma deu_u, ko_{vi} ka_{kaw-eh}se_h ma_u tcaw^h-eu qaw_u, ma_{baw} a_{ma} ja^h gha_u ba_u da neh shi_u ym^h le^h-eu ui cui^h na ja^h ga^h ya maw^h-eu meh. Ma_{baw} a_{ma} ja^h gha_u ma_u daw^h lu_{-eu} za_u mi_u a_u bu^h deu_u la_u qhoe^h, hti_u myeh^h gha_u (10000) -ah^h nyi_u gha_u, shi_u ym^h le^h-eu baw^h-aw^h, ma_{baw} a_{ma} ja^h gha_u daw^h lu_{-eu} za_u mi_u a_u bu^h deu_u hti_u myeh^h (10000) gha_{-ah}, (5) gha_u haw^h-eu (10) gha_{-ah} keu^h ni, shi_u ym^h le^h ga^h ya maw^h-eu meh. Heu^h-a_u ko_{vi} ba_u da neh pyeu_{-eu} ma_u ngeu^h-a.

18. Ko_{vi}-19, ka_{kaw-eh}se_h tcaw^h na^h, za_u ma_u pha^h baw_u nya (za_u ma_u za_u nya) meh^h leh^h eh^h-eu ngeu^h meh lo^h.

Ma_u ngeu^h-a. Mi^h tsa_u qhoe^h ta^h yu_u mui_u jaw^h sa^h do^h-eu phaw haw^h-eu a_u yui_u deu_u neh tsa_u tco^h gha_u hta_{-eu} ka_{kaw-eh}se_h deu_{-a}, za_u yoe_u beh^h-i^h-eu a^h seh^h deu_{-ah} hti_u je_{-i} ma_u choe_u ma_u ci^h-a.

19. Ko_{vi}-19, ka_{kaw}-eh_{se} tcaw[^]gha_{na} za_{yu} nya (za_{phi} nya) meh lo^ˇ.

Za_{yu} nya, za nya meh. A_{je} mi^ˇ neh eh^ˇ na^ˇ, ko_{vi} ka_{kaw}-eh_{se} ba_{da} neh, za_{yoe}, za_{jaw}chaw_{-ah} deu_{le} nya-eu ga^ˇ kaw[^] po[^] maw^ˇ hta_{-eu} hti_{je-i} ma_{ja} si_ˇ. Ko_{vi} ka_{kaw}-eh_{se} tcaw[^]-eu_{ba} da neh ghaw_{mya} je_{pyeu} la^ˇ nya-eu pha_{leh} nui noe_{dze}-aw^ˇ, za_{ma} yu^ˇ pheu_{ni} gu[^]-eu ma_{lo}-a. Aw^ˇsa_{te}leh-a[^] mi^ˇqhah_{-ah} po[^] tse^ˇ du_{hta}-eu_{la} qhoe^ˇ, ko_{vi} ka_{kaw}-eh_{se} ba_{da} neh, za_{yoe} haw^ˇ-eu, u_{ma}la_{qhoe}phi le^ˇ hta_{-eu} za_{-ah} choe^ˇle^ˇci[^]le^ˇ nya-eu hti_{je-i} ma_{ja} ga^ˇ ya maw^ˇ-eu meh.

Ko_{vi} ka_{kaw}-eh_{se}tcaw[^] hta_{gha} na^ˇ, ko_{vi} na^ˇ gaw^ˇ ba_{da} neh pyeu_{la} nya-eu, a_{ma}-eu_uma[^] la_{qhoe} u^ˇngeh neh za_{shi}-eu, heu deu_{-ah} qaw_{ma} bi pyeu_{ni} lo_{qhm} neh nya-eu je_{pyeu} meh. Leh^ˇ eh^ˇ hta_{-eu} meh.

20. Za_{phi} lu_{-eu} a_{ma} deu_{ko}vi ka_{kaw}-eh_{se} tcaw[^] nya meh lo^ˇ. Za_{phi} lu_{-eu} a_{ma} deu_{-ah} ka_{kaw}-eh_{se} a_{geu} je_{ya} tcaw[^] neh_{hta}.

Za_{phi} lu_{-eu} a_{ma} deu_{-ah}, ko_{vi} na^ˇ gaw^ˇ nyaw_{le} na^ˇ, na^ˇgaw^ˇ yaw choe_uta_u, u_{ma} la_{qhoe} phi lu_{-eu} za_{-ah} qaw_{deu} le^ˇ nya-eu mi^ˇneh, a_{chaw}-eu_{je}hu_{neh} ko_{vi}ka_{kaw}-eh_{se} tcaw[^]-eu tsa_{meh} leh^ˇ tsaw^ˇ gah^ˇ ah^ˇ-eu deu_{eh}hta_{-eu} meh. Eh^ˇqaw_{ma}, ko_{vi} ka_{kaw}-eh_{se} mya_{mya} ni-a_{za} phi lu_{-eu} a_{ma} deu_{gha}du_{noe}htm_{choe}, jah choe_{pha}-eh^ˇ, po[^] tse^ˇ du_{hta}-eu_{ma} ja[^]-eu mi^ˇneh, tcaw[^] ma leh^ˇ ngeu^ˇ na^ˇ, ka_{kaw}-eh_{se} tcaw[^]-eu_{ba} da neh pyeu_{la} nya-eu, yaw mui_{yaw} doe^ˇ (kao^ˇco^ˇ, so^ˇco^ˇ) haw^ˇeu, ma_{tcaw}na^ˇ, ko_{vi} na^ˇ gaw^ˇ ba_{da} neh pyeu_{la} nya-eu ma_{mui}-eu je_{(so}co^ˇ) a_{geu} je_{khah} dzeh_{nga} leh^ˇ, si_{du}dzeh_{nya}-eu sa_{la}ghon_{deu}neh_{-eh} baw_{dza}-aw^ˇ, ya tcaw[^] meh.

21. A_{choe} daw^ˇ za_ama deu_{-ah} ka_{kaw}-eh_{se} tcaw[^] neh_{nya} meh lo^ˇ.

A_{choe} daw^ˇ za_ama deu_{qaw} nui deu_{lo}-eh^ˇ ko_{vi} ka_{kaw}-eh_{se} tcaw[^] nya-aw^ˇ, ka_{kaw}-eh_{se} tcaw[^]gha_{na} za_{-ah} a_{choe} bi daw^ˇ nya-eu ga^ˇ kaw[^] mi^ˇtsa_{qhoe}ta[^] yu_{mui} jaw^ˇ sa[^] do[^]-eu phaw haw-eu a_{yui}deu_{eh}hta_{-eu} meh. Eh^ˇ hta_{-eu} lo_{-eh} a^ˇ po[^] ya tcaw[^] byah meh.

22. Yam_{law}-ah^ˇ pyeu_{-eu} To[^]koe^ˇ(Common cold/ seasonal flu) na^ˇ lu_{ngeh}, ko_{vi}-19, ka_{kaw}-eh_{se} tcaw[^] nya meh lo^ˇ. To[^]koe^ˇ-eu_{ka}kaw-eh_{se} tcaw[^]gha_{na}, a^ˇkha_amya[^] nah bi kha^ˇ-aw^ˇ, ko_{vi} ka_{kaw}-eh_{se} tcaw[^] nya hta.

To[^]koe^ˇ (Common cold/ seasonal flu) na^ˇ lu_{ngeh}, ko_{vi}-19, ka_{kaw}-eh_{se} ma_{ya} tcaw[^]-a. Na^ˇ gaw^ˇ hta_{le} gha_{-aw} neh teh_{-eh} ko_{vi} ka_{kaw}-eh_{se} tcaw[^]-eu tsa_{meh}.

To[^]koe^ˇ ka_{kaw}-eh_{se} tcaw[^]gha_{hta} na^ˇ, qha^ˇhte_{-eu} hti_{jaw}, (7) nah kha_{-i}-aw^ˇ neh haw^ˇ-eu, ko_{vi} ka_{kaw}-eh_{se} ya tcaw[^] meh.

23. To^koe^ ka_kaw-eh_se^ (Flu vaccine) tcaw^ gha_hta_na^, ko_vit-19, ka_kaw-eh_se^ ma_tcaw^ qaw_geu_nya meh lo^.

To^koe^ ka_kaw-eh_se^ (Flu vaccine) heu-a_, to^koe^ na^ gaw^ ma_ngeu^ na^ ma_ ka_kaw-eh_nya-a. Ko_vit na^ gaw-ah^ ma_ ka_kaw-eh_nya-a. Qhoe^ mi^ neh, to^koe^ ka_kaw-eh_se^ tcaw^ gha-eu_ qaw_ ko_vit ka_kaw-eh_se^ tcaw^-eu lo_meh. Ko_vit ka_kaw-eh_se^ haw^-eu, to^koe^ ka_kaw-eh_se^ yaw kha_qha^ hte_-eu hti_jaw (7) nah, bi kha-aw^ ya tcaw^ meh.

24. Ko_vit ka_kaw-eh_se^ yaw beh po^ tcaw^ gha_-aw^, nyi_po^ hti_po^ tcaw^-i^ ngeh, yaw beh po^ tcaw^-eu_je_ ma_ja^ na^, ma_du^ le^-eu yaw_je_ yaw_tcaw^ nya meh lo^.

Mi^t_sa_qhoe^ ta^ yu_mui_jaw^ sa^ do^-eu phaw haw-eu a_yui_deu_law nm^-a_, du^le^-eu a_yaw_hti_je_teh_-eh^ a^po^ ya tcaw^ byah meh. Leh^ eh^ hta-eu_meh. Ma_du^le^-eu ka_kaw-eh_se^ (hti_po^hti_je_) tcaw^ pha^-eu ga^ kaw^-ah^ ta_le-aw^, mi^qhah_hti_pa^ na_deu_po^ tse^ lu_-eu qaw_i_nah keu^ ni yaw mui_, yaw doe^ po^ du_hta-eu_ma_ja^ a_si_. Eh^qaw_yaw beh po^ tcaw^-eu_je_ma_pha^ za_nya-eu_nga^ leh^ ngeu^na^, mi^t_sa_qhoe^ ta^ yu_mui_jaw^ sa^ do^-eu phaw haw-eu a_yui_deu_neh, hteh_tsa^,(a_ye^paw_), zm_nya meh leh^, a_khaw-a_bi_hta_-eu_noe_hm_choe^,jah choe^-eu, ka_kaw-eh_se^-ah^, sa_la_ghon_neh_-eh^ baw_dza_-aw^, tcaw^-eu tsa_meh.

25. Ka_kaw-eh_se^ yaw beh po^ tcaw^ gha-aw^, nyi_po^ hti_po^ tcaw^ yam_tsa_la^-eu_qaw_ma_ya tcaw^ pyeu_-eu_na^, du^ le^-eu ja^ gha_a_geu ngeh yam_-ah^ pha^ ya tcaw^ hta. (ma_ngeu^ na^) Ma_du^ le^-eu ja^ gha_qhoe^ a^yam_a^myah ni kha-i^-aw^, a^mya^ po^ pha^ ya tcaw^ hta.

Ko_vit ka_kaw-eh_se^-eu_gha_hti_lo_ za_nya ni, pa^hta_-eu_a^yam_la_qhoe^ ja^gha_a^ po^ tcaw^ byah-eu a_ye^hui_meh.

Nyi_po^ hti_po^ tcaw^-eu a^yam_nah pa^ pa^-eu_qhoe^, ja^gha_hti_je_hiti_je_ma_du^le^-a. Ja^gha_hti_pa^ na_deu_nyi_po^ a^kha_ (21) nah bi kha-aw^, ja^gha_nui_deu_-a_ (28) ah^ neh (42) nah keu^ ni bi kha^-eu meh. Nah pa^ a^ nah ma_bi_bu_-i^ni ja^gha_a^po^ tcaw^ byah na^, na^ gaw^-ah^ ka_kaw-eh_nya dzeh_-eu meh. Ga^ kaw^ ghaw_myajebadaneh, nah pa^ pa^ hta_-eu_a^ nah bu_-i^ ngeh keu^ ni, nyi_po^ hti_po^ ma_ya tcaw^ na^, a_jo^jah^ neh qaw_ya tcaw^ pha_-eh^ sa_la_ghon_deu_neh_-eh^ baw_dza_-aw^ qha^ ja^ ga^ i-aw^ yaw khaw-eh^ tcaw^-eu tsa_meh. Hti_po^ teh_-eh^ tcaw^-eu_haw^-eu, nyi_po^ tcaw^ byah-eu_deu_na^ gaw^ ka_kaw-eh_-eu phaw beu ga^-eu meh.

26. Ko_vit-19, ka_kaw-eh_se^ (2) po^ tcaw^ gha-eu_tsaw^ha_-ah^, a_je_mih neh ko_vit-19 na^ gaw^ nyaw_le^-eu hta.

Ko_vit-19, ka_kaw-eh_se^ gheh_nui_je_ka_kaw-eh_se^ lo_-eh^ du_-eu teh_meh. Ka_kaw-eh_se^ tcaw^ gha_-aw^, na^ gaw^ lo_qhm_nya-eu a^ti^-ah^ keu^ le^ ni qha^ hte_-eu jaw^ nah

nyi₂ jaw, (14) nah ga-eu meh. Tsaw^h ha₂ hti₂ gha₂ ka₂kaw-eh₂se^h ma₂ tcaw^h-eu₂ mi na^h-eh^h, ma₂ ngeu^h na^h qaw₂ tcaw^h gha₂-aw^h, jaw^h nah nyi₂ jaw la₂ qhoe^h, a₂ yaw₂-eu₂ la₂ qhoe^h na^h gaw^h a^h maw^h u^h le^h gha₂ hta₂-eu₂ ngeu^h na^h, ka₂kaw-eh₂se^h tcaw^h gha₂ hta₂-eu₂ qaw₂, na^h gaw^h nyaw₂ le^h nya meh. Ka₂kaw-eh₂se^h a₂ geu je₂ ma₂ kha₂ na^h gaw^h ma₂ bi nyaw₂ la^h ni 100% ma₂ lo₂ qhm₂ nya-eu lo₂-eh^h, tsaw^h ha₂ hti₂ gha₂-eu₂ a^hqo₂-ah^h neh ma₂-eh^h, gha₂ byah, ma₂ byah-eu ga^h neh ma₂ eh^h, boe₂ baw, ma₂ baw ga^h neh ma₂ eh^h kha₂-i^h-eu meh.

Ka₂kaw-eh₂se^h tcaw^h gha₂ hta₂-eu₂ qaw₂ hti₂ pa^h na deu₂ ko₂vi^h nyaw₂ le^h-eu meh. Qhoe^h lo₂-eh^h nyaw₂ le^hga^h ka₂kaw-eh₂se^h-ah^h htah₂ gha₂-aw^h nyaw₂ la^h-eu₂ (**vaccine breakthrough cases**) leh^h khu^h-eu meh.

27. Ko₂vi^h-19 ka₂kaw-eh₂se^h nyi₂ po^h tcaw^h gha₂-eu₂ ga^h ko₂vi^h nyaw₂ le^h-aw^h, na^h-eu hta₂ le₂ gha₂ na^h, ko₂vi^h ka₂kaw-eh₂se^h pha^h ya tcaw^h meh si₂ lo^h.

Ko₂vi^h ka₂kaw-eh₂se^h tcaw^h gha₂ hta₂-eu₂ qaw₂ na^h gaw^h nyaw₂ la^h nya meh. A₂ je₂ mi^h neh eh^h na^h, la₂ ta^h phaw eh^h dzeu^h ya₂-eu₂ lo₂-eh^h, ja^h gha₂-ah^h htah₂ gha₂-aw^h nyaw₂ la^h nya-eu lo₂-eh^h, na^h gaw^h a^h maw^h a^h jeu₂ pha-i^h-eu₂ mi^h neh qaw₂ nyaw₂ la^h-nya-eu meh. Eh^hqaw₂, ka₂kaw-eh₂se^h tcaw^h dzeu^h hta₂-eu₂ tsaw^h ha₂ deu₂-a₂, na^h gaw^h pha^h nyaw₂ la^h law haw^h qaw₂ ma₂ ya na^h choe₂-a. Ko₂vi^h ka₂kaw-eh₂se^h tcaw^h gha₂-eu₂ ga^h, na^h gaw^h nyaw₂ la-aw^h, na^h-eu hta₂ le^h gha₂ na^h, ka₂kaw-eh₂se^h pha^h ya tcaw^h po^h-eu gha^h du₂ mi^h tsa₂ qhoe^h ta^h yu₂ mui₂ jaw^h sa^h do^h-eu phaw haw-eu a₂ yui₂ deu₂ ma₂ eh^h hta₂-a₂.

28. Ko₂vi^h-19 ka₂kaw-eh₂se^h (2) po^h tcaw^h gha₂-aw^h ba la heu mya^h si₂ kha-i^h na^h, ko₂vi^h-19 ka₂kaw-eh₂se^h pha^h tcaw^h nya meh lo^h.

Ko₂vi^h-19 ka₂kaw-eh₂se^h, eh^h hta₂-eu₂ a^hpo^h tcaw^h byah gha₂ hta-eu₂ tsaw^h ha₂ deu₂, ba la heu mya^h si₂ kha-i^h gha₂ na^h, ka₂kaw-eh₂se^h pha^h tcaw^h-eu, lo₂-eu, ma₂ lo₂-eu ga^h kaw^h-ah^h ta₂ le-aw^h, mi^h tsa₂ qhoe^h ta^h yu₂ mui₂ jaw^h sa^h do^h-eu phaw haw-eu a₂ yui₂ deu₂, eh^h hta₂-eu₂ ma₂ ja^h-a si₂. Ya tcaw^h po^h meh leh^h eh^h la₂ na^h, yu₂ mui₂ jaw^h sa^h do^h-eu phaw haw-eu a₂ yui₂ deu₂ na₂ ga₂ kha-eu je₂ pyeu₂ meh.

29. Ko₂vi^h-19 ka₂kaw-eh₂se^h (2) po^h tcaw^h gha₂ hta₂-eu₂ tsaw^h ha₂ deu₂ ko₂vi^h-19 ka₂kaw-eh₂se^h yaw₂ je₂ yaw₂ pha^h tcaw^h nya meh lo^h.

Ko₂vi^h-19 a^hmaw^h, (vai^hra^hs) a^h jeu₂ pha-i^h hta₂-eu₂ ba₂ da neh, na^h gaw^h yaw choe₂ haw^h-eu, na^h gaw^h ba₂ da neh, shi^h-eu je₂-ah^h lo₂ qhm₂ nya-eu gha^h du₂, mi^h tsa₂ qhoe^h ta^h yu₂ mui₂ jaw^h sa^h do^h-eu phaw haw-eu a₂ yui₂ deu₂ neh tsa₂ tco^h hta-eu₂ ka₂kaw-eh₂se^h tcaw^h-eu tsa₂ meh leh^h, (WHO) a^hmu^h eh^h hta-eu₂ meh.

Ko₂vi^h-19 ka₂kaw-eh₂se^h hti₂ je₂ je₂-ah^h, pa^h hta-eu₂ a^h nah-ah^h tsa₂ ni tcaw^h gha₂ hta-eu₂ ngeu^h na^h, ka₂kaw-eh₂se^h yaw₂ je₂ yaw₂ pha^h tcaw^h-eu ma₂ tsa₂-a. A₂ je₂ mi^h neh eh^h na^h,

mạmạdị tcaw^ pha_eḥ gheh gạ neh mạ ya tcaw^ ni lo_lu_eu tsaw^hạ deu, mạ tcaw^ni ya byeḥ-eu, ka_kaw-eh_sẹ ịdoe pha-eḥ gheh gạmạ ị doe nya-eu mịneh, nạ gaẉ je_hu ịdoe-eu, heu deu pyeu_lạ-eu mị neh, (2) po^ tcaw^ gha_ha_eu tsaw^ hạ deu, ma_ya tcaw^ po^a. Leḥ eḥ-eu meh.

Mịqhah_hti pa^ na deu, ka_kaw-eh_sẹ sm_po^ tcaw^ -eu ghạdu gạ kaw^kaw^ lu-eu qaw, ka_kaw-eh_sẹ ma za ni jaw lu_eu, ịsha sha_eu mịqhah za deu-aḥ je_hu tcaw^ neh nya pha_eḥ, nyi po^tcaw^ dzeu hta_eu mị qhah_deu, ka_kaw-eh_sẹ sm_po^ tcaw^ -eu je_ha jaḥneh la leḥ mị tsa_qhoe ta^ yu mui_jaw sạ do^ -eu phaw haw-eu a_yui_deu htah sha_eu la_qhoe bi si_ha_eu meh.

Po^ do^ -eu

WHO: Novel Coronavirus-2019 - Questions and Answers

CDC: Coronavirus – Frequently Asked Questions (FAQ)

UNICEF: Novel Coronavirus – FAQ

UK National Health Service – Covid-19 Vaccine

Serum Institute: FAQ – Covishield

SOP of AstraZeneca_Storage and Thawing Use